Synlogic
Synlogic develops synthetic biotic medicines to treat urea cycle disorders and phenylketonuria.
Business Model:
Revenue: $1.7M
Employees: 51-200
Industries / Tags:
Detailed Synlogic Information
Synlogic was acquired by
Mirna Therapeutics.
The acquisition happend on 2017-05-16.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 301 Binney Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$45M
Raised Total:$257M
Social
Metrics
2,750,415Website Global Rank
6,283Website Monthly Traffic
Twitter Followers
Description
Synlogic develops synthetic biotic medicines to treat urea cycle disorders and phenylketonuria.
Contact Phone:
+16174019975
Contact Email:
Synlogic went public on 8/28/2017 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
8/28/2017
Ticker Symbol:
SYBX
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
